Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology

C Zamarron; H R Lijnen; B Van Hoef; D Collen

doi:10.1055/s-0038-1661127

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1984; 52(01): 019-023
DOI: 10.1055/s-0038-1661127

Original Article

Schattauer GmbH Stuttgart

Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology

C Zamarron

The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium

,

H R Lijnen

The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium

,

B Van Hoef

The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium

,

D Collen

The Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Belgium

› Author Affiliations

Abstract

PDF Download

Summary

The fibrinolytic and fibrinogenolytic properties of recombinant pro-urokinase (Rec-pro-UK) and recombinant urokinase (Rec- UK) obtained by expression of the human urokinase cDNA in E. coli, were compared with those of natural urokinase (Nat-UK) of urinary origin and of tissue-type plasminogen activator (t-PA) in a system, composed of a radioactive human plasma clot immersed in citrated human plasma.

The specific fibrinolytic effects of Nat-UK, Rec-pro-UK and Rec-UK were very similar, causing significant clot lysis at concentrations of 100 IU/ml plasma or more. t-PA caused equivalent degrees of clot lysis at 10-fold lower concentrations.

Activation of the fibrinolytic system in the plasma (fib- rinogenolysis), was not observed with t-PA in concentrations which induced complete clot lysis within 5 hr (20-30 IU/ml plasma). With Nat-UK and Rec-UK, all concentrations which caused significant clot lysis (100-200 IU/ml plasma) also caused extensive activation of the plasma fibrinolytic system. With Rec- pro-UK an intermediate response was obtained. The highest amounts required for complete clot lysis in 5 hr (200 IU/ml plasma) also caused significant fibrinogenolysis. At intermediate concentrations (50-100 IU/ml), however, significant clot lysis (40-80%) was observed without systemic fibrinolytic activation.

Keywords

Recombinant pro-urokinase - Fibrinolytic versus fibrinogenolytic ratio - Clot-selectivity - Inhibition of urokinase in plasma

PDF (297 kb)

References

References
1 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-2169
2 Bernik MB. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 1973; 52: 823-834
3 Sumi H, Kosugi T, Matsuo O, Mihara H. Some properties of a high molecular form kidney tissue cultured urokinase. Abstract 3rd Congress Japanese Society Thromb Haemostas (Tokyo) 1980; 91
4 Husain SS, Gurewich V, Lipinski B. Purification of a new high MW single chain form of urokinase (UK) from urine. Thromb Haemostas 1981; 46: 11 (Abstr.)
5 Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
6 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982; 21: 6410-6415
7 Sumi H, Kosugi T, Matsuo O, Mihara H. Physicochemical properties of highly purified kidney cultured plasminogen activator (single polypeptide chain-urokinase). Acta Haematol Japon 1982; 45: 119-128
8 Husain S, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
9 Sumi H, Toki N, Sasaki K, Mihara H. Comparative properties of single and double polypeptide chains of high molecular weight urokinase. In Progress in Fibrinolysis. Vol. VI. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds) Churchill Livingstone; Edinburgh: 1983. pp 165-167
10 Heyneker HL, Holmes WE, Vehar GA. Preparation of functional human urokinase proteins. European Patent Application 83103629.8, Publication nr 0092182A2, European Patent Office Munich, West-Germany:
11 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
12 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
13 Holmberg L, Bladh B, Astedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta 1976; 445: 215-222
14 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
15 Chase T, Shaw E. Titration of trypsin plasmin and thrombin with p-nitrophenyl-p’-guanidinobenzoate. HC1. Methods Enzymol 1970; 19: 20-27
16 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
17 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulphate polyacrylamide electrophoresis. J Biol Chem 1969; 244: 4406-4412
18 Kominger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various species in vitro. Thromb Haemostas 1981; 46: 561-566
19 Gurewich V, Pannell R, Suddith R, Greenlee R. Fibrin-specificity and efficacy of proteolysis induced by single-chain urokinase (SC-UK) in plasma. Thromb Haemostas 1983; 50: 321 (Abstr.)
20 Kominger C, Collen D. Neutralization of human extrinsic (tissue- type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemostas 1981; 46: 662-665